[
    [
        {
            "time": "",
            "original_text": "面临多重困境的恒瑞医药，凭什么重夺“医药一哥”宝座？",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "多重困境",
                    "医药一哥"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "面临多重困境的恒瑞医药，凭什么重夺“医药一哥”宝座？",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "24家药企披露前三季度“成绩单”，恒瑞、天宇药业等6家下滑！",
            "features": {
                "keywords": [
                    "药企",
                    "前三季",
                    "成绩单",
                    "恒瑞",
                    "天宇药业",
                    "下滑"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "24家药企披露前三季度“成绩单”，恒瑞、天宇药业等6家下滑！",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "史上罕见！三季报后613家机构千人电话会议调研迈瑞医疗，公司回应多个热点问题",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "三季报",
                    "机构调研",
                    "热点问题"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "史上罕见！三季报后613家机构千人电话会议调研迈瑞医疗，公司回应多个热点问题",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "迈瑞医疗接受473家机构调研",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "机构调研"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "迈瑞医疗接受473家机构调研",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "迈瑞医疗（300760.SZ）：业绩稳步增长，“创新研发+并购外延”拓宽业务边界",
            "features": {
                "keywords": [
                    "迈瑞医疗",
                    "业绩增长",
                    "创新研发",
                    "并购外延"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "迈瑞医疗（300760.SZ）：业绩稳步增长，“创新研发+并购外延”拓宽业务边界",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "中信建投医药大健康团队最新研究",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药大健康",
                    "研究"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中信建投医药大健康团队最新研究",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "险资三季度首批重仓股曝光 险资三季度减持银行地产股加仓新能源与“专精特新” 减持股份数量",
            "features": {
                "keywords": [
                    "险资",
                    "三季度",
                    "重仓股",
                    "减持",
                    "银行地产",
                    "加仓",
                    "新能源",
                    "专精特新"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "新能源",
                    "专精特新"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "险资三季度首批重仓股曝光 险资三季度减持银行地产股加仓新能源与“专精特新” 减持股份数量",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]